Skip to main content
. 2013 Sep 6;305(9):L642–L650. doi: 10.1152/ajplung.00021.2013

Fig. 6.

Fig. 6.

CCSP replacement improves lung function in CCSP−/− (KO) mice post-BMT. A: lung resistance was measured by whole body plethysmography in anesthetized CCSP−/− (KO) mice that were orally intubated. n = 6 for each CCSP−/− (KO) BM and CCSP−/− (KO) BMS, n = 5 for CCSP−/− (KO) BMS + rhCCSP. *P < 0.05 for CCSP KO BMS vs. all other groups. B: representative Trichrome stain of CCSP−/− mouse lung at day 60 post-BMT with and without splenocytes with or without hrCCSP replacement, magnified ×200. C: histological scoring for lung injury of CCSP−/− (KO) mice that underwent a BMT without (BM) and with (BMS) splenocytes to induce OB at day 60 post-BMT. A separate group of BMS mice underwent weekly treatment with rhCCSP (BMS + CCSP). n = 6 for each BM and BMS, n = 5 for BMS + rhCCSP. *P < 0.08 for BMS + CCSP compared with BMS. D: cell counts of helper T cells, mature granulocytes, and monocytes from lung cryosections stained for CD4, Gr-1, and CD11b, respectively. Cell counts represent positive stained cells as a percentage of total nucleated cells, n = 3. E: inflammatory markers. Leukotriene B4 (lung homogenates) and CXCL1 (lung homogenates and serum) levels from CCSP−/− (KO) mice that underwent a BMT without (BM) and with (BMS) splenocytes to induce OB at day 60 post-BMT. A separate group of BMS mice underwent weekly treatment with rhCCSP (BMS + CCSP), n = 5 for leukotriene B4 and n = 3 for CXCL1.